Mots-clés
anticholingergics
psychosis
pdp
parkinsons disease psychosis
parkinsons disease
l-dopa
antipsychotics
levodopa
parkinson's disease
canadian diabetes association
leader
empa-reg outcome
diabetes
type 2 diabetes
liraglutide
cda guideline
macrovascular
cardiovascular outcome
empagliflozin
dyslipidemia
familial hypercholesterolemia
pcsk9 inhibitor
evolocumab
cholesterol
Tout plus
Présentations
(3)J’aime
(1)A summary of pharmaceutical microbiology part 2 - drugs
NES
•
il y a 12 ans
Mots-clés
anticholingergics
psychosis
pdp
parkinsons disease psychosis
parkinsons disease
l-dopa
antipsychotics
levodopa
parkinson's disease
canadian diabetes association
leader
empa-reg outcome
diabetes
type 2 diabetes
liraglutide
cda guideline
macrovascular
cardiovascular outcome
empagliflozin
dyslipidemia
familial hypercholesterolemia
pcsk9 inhibitor
evolocumab
cholesterol
Tout plus